| Quarterly Financials | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 64 | 64 | 75 | 79 | 71 | 72 | 99 | 95 | 69 | 68 | 74 | 72 | 71 | 88 | 76 | 75 | 65 | 78 | 87 | 107 | 95 | 101 | 103 | 106 | 69 | 87 | 97 | 119 | 83 | 94 | 98 | 110 | 73 | 91 |
| Expenses | 57 | 55 | 64 | 62 | 62 | 61 | 85 | 84 | 64 | 63 | 65 | 62 | 60 | 81 | 67 | 65 | 59 | 67 | 76 | 90 | 82 | 87 | 88 | 90 | 63 | 77 | 85 | 102 | 74 | 83 | 85 | 94 | 68 | 83 |
| EBITDA | 7 | 9 | 11 | 17 | 9 | 11 | 13 | 11 | 4 | 5 | 9 | 9 | 11 | 8 | 8 | 10 | 7 | 11 | 11 | 16 | 13 | 14 | 16 | 16 | 6 | 11 | 13 | 17 | 9 | 11 | 13 | 16 | 6 | 8 |
| Operating Profit % | 11 % | 13 % | 15 % | 13 % | 12 % | 14 % | 13 % | 11 % | 5 % | 7 % | 11 % | 10 % | 15 % | 9 % | 10 % | 12 % | 8 % | 13 % | 12 % | 14 % | 12 % | 12 % | 13 % | 15 % | 7 % | 11 % | 12 % | 13 % | 10 % | 10 % | 12 % | 13 % | 6 % | 6 % |
| Depreciation | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 |
| Interest | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 3 | 4 | 7 | 11 | 4 | 5 | 8 | 5 | -2 | -2 | 2 | 3 | 4 | 1 | 2 | 3 | 0 | 4 | 6 | 11 | 8 | 8 | 10 | 10 | 0 | 5 | 7 | 11 | 1 | 3 | 6 | 8 | -2 | -0 |
| Tax | 1 | 1 | 1 | 3 | 0 | 1 | 2 | 3 | -3 | -1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 | 2 | 4 | 2 | 3 | 3 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | -1 | 0 |
| Net Profit | 2 | 3 | 6 | 8 | 4 | 3 | 6 | 2 | 0 | -1 | 2 | 2 | 3 | 1 | 1 | 2 | 0 | 3 | 4 | 7 | 5 | 5 | 7 | 7 | 0 | 4 | 5 | 8 | 1 | 2 | 4 | 5 | -2 | -0 |
| EPS in ₹ | 2.66 | 1.79 | 7.81 | 4.84 | 2.35 | 2.08 | 3.65 | 1.43 | 0.05 | -0.37 | 0.94 | 1.41 | 2.02 | 0.73 | 0.80 | 0.95 | 0.12 | 2.00 | 2.51 | 4.33 | 3.17 | 3.35 | 1.35 | 1.48 | 0.05 | 0.85 | 0.98 | 1.66 | 0.18 | 0.49 | 0.82 | 1.01 | -0.38 | -0.09 |
Zim Laboratories
Zim Laboratories
72.59
-1.40
(-1.89%)
Key Fundamentals
Market Cap
360.50 Cr
EPS
2.50
PE Ratio
54.04
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
128.00
52 Week Low
67.00
PB Ratio
1.41
Debt to Equity
0.47
Sector
Pharmaceuticals Actual
Company News
View All News
ZIM Laboratories posted INR 887 million operating income in Q2 FY26, up 23.6% sequentially, with EBITDA improving to 8.8% from 7.9% in Q1, while continuing EU-GMP remediation efforts targeting March 2026 audit completion. The company expects FY26 revenues to match FY25 levels and has initiated site transfers for key products including Tamsulosin Dutasteride to maintain business continuity during regulatory clearance delays.
ZIM Laboratories Limited announced its quarterly results for the quarter and half year ended September 30, 2025. The company reported a standalone net loss of Rs 187.49 lakhs for Q2, compared to a profit of Rs 145.16 lakhs in the same quarter last year. For the half year, the standalone loss was Rs 229.95 lakhs versus a profit of Rs 293.58 lakhs in the previous year. Total standalone income for Q2 was Rs 9,075.43 lakhs compared to Rs 9,346.44 lakhs in Q2 FY2025. The consolidated results showed similar trends with Q2 net loss of Rs 187.49 lakhs and half-year loss of Rs 229.95 lakhs. The company entered into an agreement to sell unused MIDC leasehold land along with building and certain assets, expected to complete before March 31, 2026. Additionally, the company purchased MIDC leasehold land adjacent to its existing plant after the quarter end. The results were reviewed by Deloitte Haskins Sells LLP and approved by the Board of Directors on November 12, 2025.
ZIM Laboratories Seeks Shareholder Approval for Re-appointment of Two Whole-time Directors via Postal Ballot
Oct 13, 2025
Oct 13, 2025ZIM Laboratories Limited has issued a postal ballot notice seeking shareholder approval for the re-appointment of Mr. Niraj Dhadiwal and Mr. Prakash Sapkal as Whole-time Directors for a two-year term from October 1, 2025, to September 30, 2027. The e-voting period runs from October 15 to November 13, 2025. Both directors will receive remuneration packages including fixed salary up to Rs. 1.50 crores and performance-linked incentives up to Rs. 50 lakhs, along with perquisites such as medical insurance, car with driver, and telephone facilities. The company has appointed Ms. Roshni Jethani as scrutinizer for the postal ballot process, with results to be announced by November 15, 2025. Both directors have over 30 years of experience in the pharmaceutical sector, with Dhadiwal focusing on business development and Sapkal on operations.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,763.90 | #1 4,21,587.10 | 40.36 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 72.45 | |
6,518.50 | 1,72,859.90 | 69.69 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.21 | |
3,819.40 | 1,29,685.50 | 60.36 | 11,539.40 | 6.99 | 1,911 | 30.46 | 68.95 | |
1,535.60 | 1,23,756.00 | 22.84 | 28,409.50 | 7.12 | 5,291 | 3.71 | 49.08 | |
1,244.40 | 1,03,992.90 | #1 18.10 | 33,741.20 | 16.73 | 5,725 | -0.38 | 52.18 | |
934.75 | 95,033.80 | 18.69 | 23,511.00 | 18.55 | 4,615 | 34.60 | 34.63 | |
2,052.10 | 93,876.80 | 21.56 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 64.79 | |
2,247.00 | 93,576.50 | 52.23 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 31.45 | |
1,236.90 | 71,003.00 | 21.19 | 32,345.60 | 9.43 | 3,484 | 3.81 | 75.20 | |
5,723.00 | 68,421.10 | 28.39 | 13,458.30 | 3.70 | 2,216 | 10.98 | 64.57 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
3.27 %
Net Income Growth
-29.07 %
Cash Flow Change
152.76 %
ROE
-33.24 %
ROCE
-9.59 %
EBITDA Margin (Avg.)
3.13 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 265 | 256 | 259 | 298 | 329 | 325 | 325 | 342 | 342 | 447 | 472 |
| Fixed Assets | 87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 |
| Current Assets | 168 | 154 | 154 | 173 | 194 | 182 | 192 | 212 | 191 | 228 | 231 |
| Capital Work in Progress | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 71 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 |
| Total Liabilities | 265 | 256 | 259 | 298 | 329 | 325 | 325 | 342 | 342 | 447 | 472 |
| Current Liabilities | 133 | 122 | 113 | 141 | 155 | 143 | 142 | 146 | 111 | 159 | 166 |
| Non Current Liabilities | 38 | 35 | 28 | 20 | 22 | 28 | 22 | 20 | 30 | 49 | 53 |
| Total Equity | 94 | 99 | 118 | 137 | 151 | 154 | 161 | 176 | 200 | 239 | 252 |
| Reserve & Surplus | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 160 | 152 | 190 | 202 |
| Share Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -7 | -0 | -0 | 1 | -1 | 1 | -0 | 2 | 3 | 3 | -8 |
| Investing Activities | -9 | -12 | -7 | -26 | -21 | -19 | -6 | -14 | -36 | -73 | -40 |
| Operating Activities | 6 | 22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 |
| Financing Activities | -4 | -10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | 60 | -9 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % | 33.26 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.00 % | 0.00 % | 0.21 % | 0.01 % | 0.03 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.11 % | 0.10 % | 0.24 % | 0.24 % | 0.24 % | 0.24 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 30.73 % | 51.92 % | 51.96 % | 50.67 % | 50.77 % | 51.15 % | 50.96 % | 51.57 % | 51.57 % | 49.90 % | 50.74 % | 50.92 % | 49.01 % | 49.21 % | 45.48 % | 44.39 % | 47.78 % | 47.50 % | 48.20 % |
| Others | 36.01 % | 14.81 % | 14.77 % | 16.06 % | 15.97 % | 15.59 % | 15.78 % | 15.17 % | 15.16 % | 16.84 % | 15.99 % | 15.82 % | 17.72 % | 17.42 % | 21.15 % | 21.90 % | 18.71 % | 18.96 % | 18.30 % |
| No of Share Holders | 4,600 | 4,887 | 4,610 | 3,646 | 3,561 | 3,569 | 3,643 | 5,595 | 5,879 | 8,982 | 15,305 | 17,342 | 17,100 | 17,483 | 17,716 | 17,450 | 17,448 | 16,641 | 17,282 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
 Bonus | 1:1 | 04 Oct 2018 | 55.33 | 0.00 | |
| 29 Jun 2022 |  Extraordinary General Meeting | NA | 29 Jun 2022 | 77.67 | 63.50 |
| 22 Dec 2022 | Bonus | 2:1 | 22 Dec 2022 | 105.18 | 110.83 |
| 27 Jun 2024 |  Annual General Meeting | NA | 27 Jun 2024 | 102.30 | 105.00 |
| 09 Nov 2024 |  Quarterly Result Announcement | NA | 09 Nov 2024 | 106.99 | 113.35 |
| 10 Feb 2025 | Quarterly Result Announcement | NA | 10 Feb 2025 | 101.05 | 106.72 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 88.41 | 92.99 |
| 27 Jun 2025 | Annual General Meeting | NA | 27 Jun 2025 | 88.14 | 112.62 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 111.70 | 79.30 |
| 12 Nov 2025 | Quarterly Result Announcement | NA | 12 Nov 2025 | 73.32 | 77.62 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript7 hours ago
7 hours agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome2 days ago
2 days ago Shareholder Meeting / Postal Ballot-Scrutinizer"s Report3 days ago
3 days agoShareholder Meeting / Postal Ballot-Outcome of Postal_Ballot3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation5 days ago
5 days agoResults- Quarter And Half Year Ended 30Th September 20255 days ago
5 days agoBoard Meeting Outcome for Outcome Of Board Meeting Held On 12Th November 20255 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoBoard Meeting Intimation for Considertaion And Approval Of Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30Th September 2025Nov 05, 2025
Nov 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 14, 2025
Oct 14, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotOct 13, 2025
Oct 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSSep 19, 2025
Sep 19, 2025Announcement under Regulation 30 (LODR)-Change in ManagementSep 19, 2025
Sep 19, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Aug 07, 2025Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-AcquisitionAug 07, 2025
Aug 07, 2025Results- Financial Results For Quarter Ended 30Th June 2025Aug 07, 2025
Aug 07, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 07Th August 2025Aug 07, 2025
Aug 07, 2025Reply To Clarification Sought On Price MovementAug 07, 2025
Aug 07, 2025Clarification Sought On Movement Of Price Of The CompanyAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 06, 2025
Aug 06, 2025Clarification sought from Zim Laboratories LtdAug 06, 2025
Aug 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 04, 2025
Aug 04, 2025Announcement Under Regulation 30 Of The SEBI (LODR) Regulations 2015Aug 01, 2025
Aug 01, 2025Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended 30Th June 2025.Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 28, 2025
Jul 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Jul 22, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 21, 2025
Jul 21, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJul 11, 2025
Jul 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 10, 2025
Jul 10, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportJun 27, 2025
Jun 27, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMJun 27, 2025
Jun 27, 2025Closure of Trading WindowJun 26, 2025
Jun 26, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionJun 19, 2025
Jun 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 17, 2025
Jun 17, 2025Reg. 34 (1) Annual Report.Jun 05, 2025
Jun 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 04, 2025
Jun 04, 2025Announcement Under Regulation 30 - Letters Sent To ShareholdersJun 03, 2025
Jun 03, 2025Notice Of The 41St Annual General Meeting Of The CompanyJun 03, 2025
Jun 03, 2025Reg. 34 (1) Annual Report.Jun 03, 2025
Jun 03, 2025Intimation Of Annual General Meeting To Be Held On Intimation Of Date Of Annual General MeetingJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 29, 2025
May 29, 2025Technical Indicators
RSI(14)
Neutral 52.31
ATR(14)
Less Volatile 3.70
STOCH(9,6)
Neutral 39.14
STOCH RSI(14)
Neutral 47.86
MACD(12,26)
Bullish 0.45
ADX(14)
Strong Trend 32.07
UO(9)
Bearish 49.04
ROC(12)
Uptrend And Accelerating 7.34
WillR(14)
Neutral -61.19
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
